Consulting services for drug discovery, disease biology, company creation, etc.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme is focused on the discovery and development of inhibitors of histone methyltransferases for therapeutic intervention in cancer indications.• Department head for group of 25 biologists, responsible for target validation, computational biology, cell-based assay development, in vivo cancer biology (lead optimization), translational biology, and clinical PD supporto 2 first-in-class clinical-stage programs (pinometostat for DOT1L and tazemetostat for EZH2)o 3 campaigns to deliver developmental candidates (GSK Alliance); including a first-in-class PRMT5 inhibitor (clinical candidate GSK3326595 (EPZ015938))o Implemented a robust functional genomics platform for identification of epigenetic targets for oncology indications  Greater than 70 target-disease relationships identified Five prioritized targets for drug discovery (HMT and non-HMT; goal of 3 new INDs by 2020)o Pioneering in the field of cancer epigenetics, including robust publication record and intellectual property filings• Championed Epizyme’s first non-oncology drug discovery program: G9A developmental candidate for the treatment of sickle cell disease (to be presented at ASH, 2017)• Responsible for communicating company’s scientific vision and status updates to diverse audiences: investors, BD, PR, KOLs and broader scientific community (2015-)• Member of Executive Leadership Team• Member of GSK Alliance Joint Steering Committee • Member of Celgene Alliance Joint Steering Committee

Head of Platform Biology Group-Target identification and validation

Team Leader, Cell Biology Group. • Managed 2 Ph.D. and 2-3 Research Associates• Developed 3 novel cell based assays for profiling small molecule SIRT1 activators in support of SAR efforts• Lead efforts to utilize systems biology approach to elucidate the molecular mechanisms underlying compound efficacy in vivo• Co-recipient of Bio-IT World’s 2008 Best Practices Award in the Drug Discovery category• Identified and validated mechanism-based biomarker for SIRT1 activators in pre-clinical models of metabolic disease• Significant contributions to due diligence efforts preceding the GSK acquisition of Sirtris (May 2008)

Target Research Group; studied the targets and mechanism of action of ARQ 501, a Phase II clinical trial cancer therapeutic• Identified an ARQ 501 molecular target in cell culture systems• Elucidated ARQ 501 molecular mechanism of action• Developed two assays based on ARQ 501 MOA for use in profiling next-generation leads from ARQ 501’s chemical family• Developed a clinical assay for monitoring ARQ 501 cytotoxicity in clinical samples• Managed one Research Associate

Responsible for the development of cellular microarray technology• Developed a novel, multiplexed GPCR assay using the Akceli platform• Adapted assays for cell cycle arrest, proliferation, and apoptosis for use with cellular microarray technology • Adapted RNAi technology to the cellular microarray platform • Performed data mining on cellular microarray experiments• Optimized the cellular microarray printing process• Managed one Research Associate